HOWL — Werewolf Therapeutics Share Price
Last trade - 00:00- $255.75m
- $160.73m
- $19.94m
- 31
- 16
- 73
- 34
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.3 | ||
| Price to Tang. Book | 2.3 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 12.82 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -26.05% | ||
| Return on Equity | -31.98% | ||
| Operating Margin | -203.09% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 16.4 | 19.94 | 5.83 | 12.38 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Werewolf Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Its product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. WTX-124 is in development as a monotherapy and in combination with pembrolizumab in multiple solid tumor types. WTX-330 is in development as a single agent in metastatic solid tumors and non-Hodgkin lymphoma. Its pipeline also includes JZP898 and WTX-712.
Directors
- Luke Evnin NEC (57)
- Daniel Hicklin PRE (57)
- Timothy Trost CFO (63)
- Reid Leonard COO (62)
- Chulani Karunatilake CTO
- Cynthia Seidel-Dugan CSO (62)
- William Winston VPR
- Randi Isaacs OTH (65)
- Ellen Lubman OTH (45)
- Meeta Chatterjee DRC (66)
- Michael Sherman DRC (55)
- Sakae Asanuma IND (54)
- Derek Di Rocco IND (41)
- Alon Lazarus IND (46)
- Briggs Morrison IND (62)
- Elise Wang IND (61)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- October 19th, 2017
- Public Since
- April 30th, 2021
- No. of Shareholders
- 21
- No. of Employees
- 47
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 43,347,363
- Address
- 200 Talcott Avenue, 2Nd Floor, WATERTOWN, 02472
- Web
- https://werewolftx.com/
- Phone
- +1 6179520555
- Auditors
- Deloitte & Touche LLP
Upcoming Events for HOWL
Similar to HOWL
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 19:24 UTC, shares in Werewolf Therapeutics are trading at $5.90. This share price information is delayed by 15 minutes.
Shares in Werewolf Therapeutics last closed at $5.90 and the price had moved by +143.8% over the past 365 days. In terms of relative price strength the Werewolf Therapeutics share price has outperformed the S&P500 Index by +102.88% over the past year.
The overall consensus recommendation for Werewolf Therapeutics is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Werewolf Therapeutics does not currently pay a dividend.
Werewolf Therapeutics does not currently pay a dividend.
Werewolf Therapeutics does not currently pay a dividend.
To buy shares in Werewolf Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $5.90, shares in Werewolf Therapeutics had a market capitalisation of $255.75m.
Here are the trading details for Werewolf Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: HOWL
Based on an overall assessment of its quality, value and momentum Werewolf Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Werewolf Therapeutics is $12.50. That is 111.86% above the last closing price of $5.90.
Analysts covering Werewolf Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.32 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Werewolf Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +145.54%.
As of the last closing price of $5.90, shares in Werewolf Therapeutics were trading +53.51% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Werewolf Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.90.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Werewolf Therapeutics' management team is headed by:
- Luke Evnin - NEC
- Daniel Hicklin - PRE
- Timothy Trost - CFO
- Reid Leonard - COO
- Chulani Karunatilake - CTO
- Cynthia Seidel-Dugan - CSO
- William Winston - VPR
- Randi Isaacs - OTH
- Ellen Lubman - OTH
- Meeta Chatterjee - DRC
- Michael Sherman - DRC
- Sakae Asanuma - IND
- Derek Di Rocco - IND
- Alon Lazarus - IND
- Briggs Morrison - IND
- Elise Wang - IND